Skip to NavigationSkip to content

News

0
European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit
Voices in the industry are questioning the EU’s decision to reserve at least 500,000 courses of the therapy on 8 October when it may be of limited...
0
Pfizer won’t apply for COVID-19 vaccine emergency authorisation until after US election, CEO says
“Based on our current trial enrolment and dosing pace, we estimate we will reach this milestone in the third week of November,” Pfizer CEO Albert...
0
UK life sciences industry does not want no-deal Brexit, says ABPI Chief
In the event the UK leaves on no-deal terms, there is fear that this could lead to a duplication of standards and regulations across the two...
0
Sanofi's Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis
The backing is specific to patients between the ages of six and 11 who are eligible for systemic therapy.
>> More News Stories

Features

Oncology research in the age of COVID-19

Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive...

>> More Features
>> More News Stories